ARK Genomic Revolution ETF vs T Rowe Price Group Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.36, while T Rowe Price Group Inc trades at $116.99 (market cap $24.26B). The key difference: T Rowe Price Group Inc pays a 4.57% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, T Rowe Price Group Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | TROW | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $44.55 | $121.68 |
52-Week Low | $24.02 | $86.19 |
Market Cap | — | $24.26B |
Enterprise Value | — | $21.46B |
Dividend Yield | — | 4.57% |
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →